Search filters

Filters

Clear All

Phase

  • 67
  • 71
  • 1
  • 86
  • 1
  • 61
  • 13
  • 203
  • 578
  • 220
  • 9
  • 25
  • 548
  • 578
  • 4

Found 582 Barrett's Esophagus trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 GGDEF-32 Trident

GGDEF-32 Trident

All genders
The primary objective is to determine if TTFields to the brain concomitantly with RT and TMZ in the treatment of GBM patients prolongs the overall survival of patients, compared to RT and TMZ followed by TTFields and maintenance TMZ. Secondary objectives assess progression-free survival, 1 and 2 year survival rates, …

UPCC 19418: A Phase 1/2a Dose-Finding Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma

All genders
Phase 1
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …
 Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease.

Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease.

18 years - 99 years
All genders
Phase 3
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD. Five hundred and fifty-two (552) evaluable subjects will be enrolled in this study, and will undergo SPECT MPI and Flurpiridaz (18F) Injection PET MPI, …
 APPRAISE Study- Assessment of Primary Prevention Patients Receiving An ICD

APPRAISE Study- Assessment of Primary Prevention Patients Receiving An ICD

21 years - 99 years
All genders
The value of Antitachycardia Pacing (ATP) in primary prevention patients who receive implantable cardioverter defibrilator (ICDs) is uncertain. The purpose of this study is to better understand the value of ATP in primary prevention patients. This study is to see if certain programing will reduce the number of shocks received …

CART-38 in Adult AML and MM Patients - 1

All genders
Phase 1
Interventional
Primary hyperparathyroidism is a significant medical and public health problem in the world and affects approximately 100,000 new patients in the United States alone. If left untreated this can lead to renal stones, osteoporosis, fatigue, and depression. The best treatment for primary hyperparathyroidism is surgical parathyroidectomy. However surgical parathyroidectomy can …
 A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

18 years - 90 years
All genders
Phase 2
Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®. Betalutin® is made by using a new antibody, called lilotomab, and attaching a radioactive molecule …
 An Open-Label  Safety and Tolerability Phase 1b Trial of CAN04  A Fully Humanized Anti-IL1RAP Monoclonal Antibody  in Combination with Pembrolizumab in Subjects with Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-Containing Regimens

An Open-Label Safety and Tolerability Phase 1b Trial of CAN04 A Fully Humanized Anti-IL1RAP Monoclonal Antibody in Combination with Pembrolizumab in Subjects with Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-Containing Regimens

All genders
Phase 1
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination …
 PROACTIVE: Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet

PROACTIVE: Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet

18 years - 70 years
All genders
Phase 2
Approximately 50% of patients with celiac disease have continued symptoms despite at least 12 months of treatment with a gluten free diet. PRV-015, a mAb that blocks IL-15, has been shown to reduce intestinal inflammation and improve clinical symptoms induced by gluten consumption in a previous Phase 2a gluten-challenge study …
 Size and Decay of HIV-1 Reservoirs in Tissues and Cerebrospinal Fluid in Participants on Long-Term Antiretroviral Therapy

Size and Decay of HIV-1 Reservoirs in Tissues and Cerebrospinal Fluid in Participants on Long-Term Antiretroviral Therapy

18 years - 99 years
All genders
The purpose of this study is to look at where human immunodeficiency virus (HIV) might be “hiding” when standard lab tests show that HIV levels in the blood are very low.
 Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naive and Bevacizumab Resistant Recurrent Glioblastoma

Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naive and Bevacizumab Resistant Recurrent Glioblastoma

18 years - 99 years
All genders
Phase 2
This is a multicenter, open-label, phase II trial of pembrolizumab plus re-irradiation among recurrent glioblastoma patients enrolled to two parallel, non-comparative treatment arms including patients who are bevacizumab naïve (Arm A, n=30) and patients who are bevacizumab-resistant (Arm B, n=30). All subjects must have histologically confirmed World Health Organization (WHO) …
471 - 480 of 582